Abstract
Remarkable in vitro and in vivo activity of IMGN853, an antibody-drug conjugate targeting folate receptor alpha linked to the tubulin-disrupting maytansinoid DM4, in biologically aggressive (type II) endometrial cancers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have